

# AssayMax™ Human AGP2 ELISA Kit

Assaypro LLC 3400 Harry S Truman Blvd St. Charles, MO 63301 T (636) 447-9175 F (636) 395-7419 www.assaypro.com

For any questions regarding troubleshooting or performing the assay, please contact our support team at support@assaypro.com.

Thank you for choosing Assaypro.

## **Assay Summary**

**Step 1**. Add 50  $\mu$ l of Standard or Sample per well. Incubate 2 hours.

**Step 2.** Wash, then add 50  $\mu$ l of Biotinylated Antibody per well. Incubate 1 hour.

**Step 3**. Wash, then add 50  $\mu$ l of SP Conjugate per well. Incubate 30 minutes.

**Step 4.** Wash, then add 50  $\mu$ l of Chromogen Substrate per well. Incubate 20 minutes.

**Step 5.** Add 50  $\mu$ l of Stop Solution per well. Read at 450 nm immediately.

## **Symbol Key**



Consult instructions for use.

# **Assay Template**

| 12 |   |   |   |   |   |   |   |   |
|----|---|---|---|---|---|---|---|---|
| 11 |   |   |   |   |   |   |   |   |
| 10 |   |   |   |   |   |   |   |   |
| 6  |   |   |   |   |   |   |   |   |
| ∞  |   |   |   |   |   |   |   |   |
| 7  |   |   |   |   |   |   |   |   |
| 9  |   |   |   |   |   |   |   |   |
| .c |   |   |   |   |   |   |   |   |
| 4  |   |   |   |   |   |   |   |   |
| ю  |   |   |   |   |   |   |   |   |
| 2  |   |   |   |   |   |   |   |   |
| 1  |   |   |   |   |   |   |   |   |
|    | Ą | В | 3 | Q | 3 | Ŧ | 9 | I |

# AssayMax™ Human alpha-1-Acid Glycoprotein 2 (ORM2, AGP2) ELISA Kit

Catalog No. EG2713-1
Sample insert for reference use only

#### Introduction

Alpha-1-acid glycoprotein (AGP) or orosomucoid is an acute-phase plasma glycoprotein. It is synthesized in the liver and secreted into the plasma. The protein is a single polypeptide chain of 183 amino acids containing high carbohydrate content (45%) of its 41 kDa molecular weight (1). As a consequence of acute infections or inflammation, the plasma concentration of AGP increases considerably. The elevated serum level of AGP is associated with an increased risk of cardiovascular disease. Urinary AGP excretion rate predicts cardiovascular mortality in patients with Type II diabetes (2). AGP can be used as a marker for acute inflammation (3), chronic alcohol drinking (4), chronic kidney disease (5), and asthma (6).

#### Principle of the Assay

The AssayMax™ Human AGP2 ELISA (Enzyme-Linked Immunosorbent Assay) Kit is designed for detection of AGP2 in human plasma, serum, and cell culture samples. This assay employs a quantitative sandwich enzyme immunoassay technique that measures human AGP2 in approximately 4 hours. A polyclonal antibody specific for human AGP2 has been pre-coated onto a 96-well microplate with removable strips. AGP2 in standards and samples is sandwiched by the immobilized antibody and a biotinylated polyclonal antibody specific for human AGP2, which is recognized by a streptavidin-peroxidase (SP) conjugate. All unbound material is washed away and a peroxidase enzyme substrate is added. The color development is stopped and the intensity of the color is measured.

## **Caution and Warning**

- This product is for Research Use Only and is not intended for use in diagnostic procedures.
- Prepare all reagents (diluent buffer, wash buffer, standard, biotinylated antibody, and SP conjugate), as instructed, prior to running the assay.
- Prepare all samples prior to running the assay. The dilution factors for the samples are suggested in this insert. However, the user should determine the optimal dilution factor.

- Spin down the SP conjugate vial, the biotinylated antibody vial, and the standard diluent vial before opening and using contents.
- The Stop Solution is an acidic solution.
- The kit should not be used beyond the expiration date.

#### Reagents

- Human AGP2 Microplate: A 96-well polystyrene microplate (12 strips of 8 wells) coated with a polyclonal antibody against human AGP2.
- Sealing Tapes: Each kit contains 3 precut, pressure sensitive sealing tapes that can be cut to fit the format of the individual assay.
- Human AGP2 Standard: Human AGP2 in a buffered protein base (240 ng, lyophilized).
- **Biotinylated Human AGP2 Antibody (50x):** A 50-fold concentrated biotinylated polyclonal antibody against human AGP2 (120 µl).
- MIX Diluent Concentrate (10x): A 10-fold concentrated buffered protein base (30 ml).
- Standard Diluent (1x): A buffered protein base with stabilizer (2 ml).
- Wash Buffer Concentrate (20x): A 20-fold concentrated buffered surfactant (30 ml, 2 bottles).
- SP Conjugate (100x): A 100-fold concentrate (80 μl).
- Chromogen Substrate (1x): A stabilized peroxidase chromogen substrate tetramethylbenzidine (7 ml).
- **Stop Solution (1x):** A 0.5 N hydrochloric acid solution to stop the chromogen substrate reaction (11 ml).

## **Storage Condition**

- Upon arrival, immediately store components of the kit at recommended temperatures up to the expiration date.
- Store Standard, SP Conjugate, and Biotinylated Antibody at -20°C.
- Store Microplate, Diluent Concentrate (10x), Standard Diluent (1x), Wash Buffer, Stop Solution, and Chromogen Substrate at 2-8°C.
- Unused microplate wells may be returned to the foil pouch with the desiccant packs and resealed. May be stored for up to 30 days in a vacuum desiccator.

## Other Supplies Required

- Microplate reader capable of measuring absorbance at 450 nm
- Pipettes (1-20 μl, 20-200 μl, 200-1000 μl, and multiple channel)
- Deionized or distilled reagent grade water

#### Sample Collection, Preparation, and Storage

- Plasma: Collect plasma using one-tenth volume of 0.1 M sodium citrate as an anticoagulant. Centrifuge samples at 3000 x g for 10 minutes and collect plasma. The sample is suggested for use at 1x; however, user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles (EDTA or Heparin can also be used as an anticoagulant).
- Serum: Samples should be collected into a serum separator tube. After clot formation, centrifuge samples at 3000 x g for 10 minutes and remove serum. The sample is suggested for use at 1x; however, user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles.
- Cell Culture Supernatant: Centrifuge cell culture media at 1500 rpm for 10 minutes at 4°C to remove debris and collect supernatant. If necessary, dilute samples into MIX Diluent; user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -80°C. Avoid repeated freeze-thaw cycles.

Applicable samples may also include biofluids, cell culture, and tissue homogenates. If necessary, user should determine optimal dilution factor depending on application needs.

#### Refer to Dilution Guidelines for further instruction.

|          | Guidelines for Dilutions of 100-fold or Greater (for reference only; please follow the insert for specific dilution suggested) |                |   |  |  |
|----------|--|----------------|---|--|--|
|          | 100x   | 10000x         |   |  |  |
| A)       | 4 μl sample : 396 μl buffer (100x) = 100-fold dilution  Assuming the needed volume is less than or equal to 400 μl.            | A)<br>B)       | 4 μl sample : 396 μl buffer (100x) 4 μl of A : 396 μl buffer (100x) = 10000-fold dilution Assuming the needed volume is less than or equal to 400 μl. |  |  |
| 1000x    |  |                | 100000x   |  |  |
| A)<br>B) | 4 μl sample : 396 μl buffer (100x)<br>24 μl of A : 216 μl buffer (10x)<br>= 1000-fold dilution                                 | A)<br>B)<br>C) | 4 μl sample : 396 μl buffer (100x)<br>4 μl of A : 396 μl buffer (100x)<br>24 μl of B : 216 μl buffer (10x)<br>= 100000-fold dilution                  |  |  |
|          | Assuming the needed volume is less than or equal to 240 µl.  |                | Assuming the needed volume is less than or equal to 240 µl.   |  |  |

#### **Reagent Preparation**

- Freshly dilute all reagents and bring all reagents to room temperature before use.
- MIX Diluent Concentrate (10x): Dilute the MIX Diluent Concentrate 10fold with reagent grade water to produce a 1x solution. When diluting
  the concentrate, make sure to rinse the bottle thoroughly to extract any
  precipitates left in the bottle. Mix the 1x solution gently until the crystals
  have completely dissolved. Store for up to 30 days at 2-8°C.
- Human AGP2 Standard: Reconstitute the Human AGP2 Standard (240 ng) with 0.3 ml of Standard Diluent to generate an 800 ng/ml standard stock solution. Allow the vial to sit for 10 minutes with gentle agitation prior to making dilutions. Prepare duplicate or triplicate standard points by serially diluting from the standard stock solution (800 ng/ml) 2-fold with equal volume of MIX Diluent to produce 400, 200, 100, 50, 25, 12.5, and 6.25 ng/ml solutions. MIX Diluent serves as the zero standard (0 ng/ml). Aliquot remaining stock solution to limit repeated freeze-thaw cycles. This solution should be stored at -20°C and used within 30 days.

| Standard<br>Point | Dilution   | [AGP2]<br>(ng/ml) |
|-------------------|--|-------------------|
| P1                | 1 part Standard (800 ng/ml) + 1 part MIX Diluent | 400               |
| P2                | 1 part P1 + 1 part MIX Diluent                   | 200               |
| Р3                | 1 part P2 + 1 part MIX Diluent                   | 100               |
| P4                | 1 part P3 + 1 part MIX Diluent                   | 50                |
| P5                | 1 part P4 + 1 part MIX Diluent                   | 25                |
| P6                | 1 part P5 + 1 part MIX Diluent                   | 12.5              |
| P7                | 1 part P6 + 1 part MIX Diluent                   | 6.25              |
| P8                | MIX Diluent                                      | 0.0               |

- Biotinylated Human AGP2 Antibody (50x): Spin down the antibody briefly and dilute the desired amount of the antibody 50-fold with MIX Diluent to produce a 1x solution. The undiluted antibody should be stored at -20°C.
- Wash Buffer Concentrate (20x): Dilute the Wash Buffer Concentrate 20fold with reagent grade water to produce a 1x solution. When diluting
  the concentrate, make sure to rinse the bottle thoroughly to extract any
  precipitates left in the bottle. Mix the 1x solution gently until the crystals
  have completely dissolved.
- SP Conjugate (100x): Spin down the SP Conjugate briefly and dilute the
  desired amount of the conjugate 100-fold with MIX Diluent to produce a
  1x solution. The undiluted conjugate should be stored at -20°C.

#### **Assay Procedure**

- Prepare all reagents, standard solutions, and samples as instructed. Bring all reagents to room temperature before use. The assay is performed at room temperature (20-25°C).
- Remove excess microplate strips from the plate frame and return them
  immediately to the foil pouch with desiccants inside. Reseal the pouch
  securely to minimize exposure to water vapor and store in a vacuum
  desiccator.
- Add 50 µl of Human AGP2 Standard or sample to each well. Gently tap
  plate to thoroughly coat the wells. Break any bubbles that may have
  formed. Cover wells with a sealing tape and incubate for 2 hours. Start
  the timer after the last addition.
- Wash the microplate manually or automatically using a microplate washer. Invert the plate and decant the contents; hit 4-5 times on absorbent material to completely remove the liquid. If washing manually, wash five times with 200 µl of Wash Buffer per well. Invert the plate each time and decant the contents; hit 4-5 times on absorbent material to completely remove the liquid. If using a microplate washer, wash six times with 300 µl of Wash Buffer per well; invert the plate and hit 4-5 times on absorbent material to completely remove the liquid.
- Add 50 µl of Biotinylated Human AGP2 Antibody to each well. Gently tap
  plate to thoroughly coat the wells. Break any bubbles that may have
  formed. Cover wells with a sealing tape and incubate for 1 hour.
- Wash the microplate as described above.
- Add 50 µl of SP Conjugate to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Cover wells with a sealing tape and incubate for 30 minutes. Turn on the microplate reader and set up the program in advance.
- Wash the microplate as described above.
- Add 50 µl of Chromogen Substrate to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Incubate in ambient light for 20 minutes or until the optimal blue color density develops.
- Add 50 µl of Stop Solution to each well. The color will change from blue to yellow. Gently tap plate to ensure thorough mixing. Break any bubbles that may have formed.
- Read the absorbance on a microplate reader at a wavelength of 450 nm immediately. If wavelength correction is available, subtract readings at 570 nm from those at 450 nm to correct optical imperfections. Otherwise, read the plate at 450 nm only. Please note that some unstable black particles may be generated at high concentration points after stopping the reaction for about 10 minutes, which will reduce the readings.

#### **Data Analysis**

- Calculate the mean value of the duplicate or triplicate readings for each standard and sample.
- To generate a standard curve, plot the graph using the standard concentrations on the x-axis and the corresponding mean 450 nm absorbance (OD) on the y-axis. The best fit line can be determined by regression analysis using log-log or four-parameter logistic curve fit.
- Determine the unknown sample concentration from the Standard Curve and multiply the value by the dilution factor.

#### **Typical Data**


The typical data is provided for reference only. Individual laboratory
means may vary from the values listed. Variations between laboratories
may be caused by technique differences.

| Standard Point | ng/ml | OD             | Average OD |
|----------------|-------|----------------|------------|
| P1             | 400   | 2.460<br>2.390 | 2.425      |
| P2             | 200   | 1.876<br>1.844 | 1.860      |
| P3             | 100   | 1.195<br>1.231 | 1.213      |
| P4             | 50    | 0.684<br>0.744 | 0.714      |
| P5             | 25    | 0.392<br>0.414 | 0.403      |
| Р6             | 12.5  | 0.240<br>0.222 | 0.231      |
| P7             | 6.25  | 0.148<br>0.138 | 0.143      |
| P8             | 0.0   | 0.054<br>0.058 | 0.056      |

#### Standard Curve

 The curve is provided for illustration only. A standard curve should be generated each time the assay is performed.

#### Human AGP2 Standard Curve



#### **Performance Characteristics**

- This assay recognizes both natural and recombinant human AGP2.
- The minimum detectable dose of human AGP2 as calculated by 2SD from the mean of a zero standard was established to be 2.4 ng/ml.
- Intra-assay precision was determined by testing three plasma samples twenty times in one assay.
- Inter-assay precision was determined by testing three plasma samples in twenty assays.

|                   | Intra-Assay Precision |      |      | Inter | -Assay Pred | ision |
|-------------------|-----------------------|------|------|-------|-------------|-------|
| Sample            | 1                     | 2    | 3    | 1     | 2           | 3     |
| n                 | 20                    | 20   | 20   | 20    | 20          | 20    |
| CV (%)            | 3.8%                  | 3.5% | 5.0% | 11.5% | 9.2%        | 11.9% |
| Average<br>CV (%) | 4.1%                  |      |      |       | 10.9%       |       |

## Recovery

| Standard Added Value | 12.5 – 100 ng/ml |  |
|----------------------|------------------|--|
| Recovery %           | 87 – 115%        |  |
| Average Recovery %   | 96%              |  |

## **Cross-Reactivity**

| Species | Cross-Reactivity (%) |
|---------|----------------------|
| Canine  | 40%                  |
| Bovine  | None                 |
| Equine  | 20%                  |
| Monkey  | 80%                  |
| Mouse   | None                 |
| Rat     | 50%                  |
| Swine   | 50%                  |
| Rabbit  | None                 |
| Protein | Cross-Reactivity (%) |
| AGP1    | None                 |

• 10% FBS in culture media will not affect the assay.

## Troubleshooting

| Issue  | Causes   | Course of Action   |
|--|--|--|
|  | Use of improper components                           | Check the expiration date listed before use.     Do not interchange components from different lots.  |
|  | Improper wash step                                   | Check that the correct wash buffer is being used. Check that all wells are empty after aspiration. Check that the microplate washer is dispensing properly. If washing by pipette, check for proper pipetting technique. |
| cisio  | Splashing of reagents while loading wells            | Pipette properly in a controlled and careful manner.   |
| Low Precision                                | Inconsistent volumes loaded into wells               | <ul> <li>Pipette properly in a controlled and careful manner.</li> <li>Check pipette calibration.</li> <li>Check pipette for proper performance.</li> </ul>  |
|  | Insufficient mixing of reagent dilutions             | <ul> <li>Thoroughly agitate the lyophilized components after<br/>reconstitution.</li> <li>Thoroughly mix dilutions.</li> </ul>   |
|  | Improperly sealed<br>microplate                      | <ul> <li>Check the microplate pouch for proper sealing.</li> <li>Check that the microplate pouch has no punctures.</li> <li>Check that three desiccants are inside the microplate pouch prior to sealing.</li> </ul>     |
| w or<br>ısity                                | Microplate was left<br>unattended between<br>steps   | Each step of the procedure should be performed uninterrupted.  |
| Lo   | Omission of step                                     | <ul> <li>Consult the provided procedure for complete list of steps.</li> </ul>   |
| edly<br>al In                                | Steps performed in<br>incorrect order                | Consult the provided procedure for the correct order.  |
| Unexpectedly Low or<br>High Signal Intensity | Insufficient amount of<br>reagents added to<br>wells | Check pipette calibration.     Check pipette for proper performance.   |
| 는 if   | Wash step was skipped                                | Consult the provided procedure for all wash steps.   |
|  | Improper wash buffer                                 | <ul> <li>Check that the correct wash buffer is being used.</li> </ul>  |

|                              | Improper reagent preparation Insufficient or prolonged incubation periods | Consult reagent preparation section for the correct dilutions of all reagents.  Consult the provided procedure for correct incubation time.   |
|------------------------------|---|---|
| Deficient Standard Curve Fit | Non-optimal sample<br>dilution  | Sandwich ELISA: If samples generate OD values higher than the highest standard point (P1), dilute samples further and repeat the assay. Competitive ELISA: If samples generate OD values lower than the highest standard point (P1), dilute samples further and repeat the assay.  User should determine the optimal dilution factor for samples. |
| ında                         | Contamination of reagents   | <ul> <li>A new tip must be used for each addition of different<br/>samples or reagents during the assay procedure.</li> </ul>   |
| nt Sta                       | Contents of wells evaporate   | Verify that the sealing film is firmly in place before placing<br>the assay in the incubator or at room temperature.  |
| Deficie                      | Improper pipetting  | Pipette properly in a controlled and careful manner. Check pipette calibration. Check pipette for proper performance.   |
|                              | Insufficient mixing of reagent dilutions                                  | Thoroughly agitate the lyophilized components after reconstitution. Thoroughly mix dilutions.   |

#### References

- (1) Fournier T et al. (2000) Biochim Biophys Acta. 1482(1-2):157-171.
- (2) Christiansen MS et al. (2002) Diabetologia. 45(1):115-120.
- (3) Magid E et al. (2005) Clinical Chemistry. 51(11):2052-2058.
- (4) Tsutsumi M et al. (2001) Alcohol. 25(3):181-184.
- (5) Romao JE Jr et al. (2006) Am J Nephrol. 26(1):59-66.
- (6) Van Den Heuvel MM et al. (2000) Am J Respir Crit Care Med. 161(6):1972-1978.

Version 1.3